You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK)與武田的呋喹替尼中國以外地區許可協議已完成交易
格隆匯 03-14 21:35

格隆匯3月14日丨和黃醫藥(00013.HK)公吿,繼2023年1月23日的公吿並完成包括反壟斷審查在內的慣例成交條件後,與Takeda Pharmaceutical Company Limited(武田藥品工業株式會社)(東京證券交易所:4502;紐約證券交易所:TAK)的子公司就進一步推動呋喹替尼在中國以外地區的全球開發、商業化和生產達成的獨家許可協議已完成交易。

憑藉強大的臨牀前和臨牀特徵,呋喹替尼為難治性轉移性結直腸癌患者提供了一種潛在的新治療選擇,支持了武田及和黃醫藥改善全球癌症患者生活的共同目標。武田現在負責呋喹替尼在全球所有地區(除中國內地、香港和澳門以外)的開發、商業化和生產。呋喹替尼在中國內地、香港和澳門由和黃醫藥負責推出市場。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account